GDNF and amyotrophic lateral sclerosis: These overall encouraging results will be hopefully reinforced by the results of an analogous phase I/IIa trial from an independent ALS clinic (NCT03482050) and by an ongoing study designed to evaluate the injection of CNS10-NPC-GDNF in the motor cortex of ALS patients (NCT05306457), thus possibly corroborating the therapeutic neuroprotective power of healthy astrocytes.